Study #2022-0093
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma.
MD Anderson Study Status
Not Accepting
Treatment Agent
Ipilimumab, Nivolumab, Ciforadenant
Description
To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Renal Cell Carcinoma
Study phase:
Physician name:
Eric Jonasch
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-211-1427
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.